FIL Ltd Trims Stock Position in The Cooper Companies, Inc. (NASDAQ:COO)

FIL Ltd trimmed its holdings in The Cooper Companies, Inc. (NASDAQ:COO) by 2.0% in the 4th quarter, HoldingsChannel reports. The fund owned 371,808 shares of the medical device company’s stock after selling 7,406 shares during the quarter. FIL Ltd’s holdings in Cooper Companies were worth $34,180,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in COO. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in shares of Cooper Companies in the 4th quarter valued at approximately $691,000. Highland Capital Management LLC acquired a new stake in Cooper Companies in the 4th quarter valued at approximately $4,004,000. Caprock Group LLC purchased a new stake in Cooper Companies in the fourth quarter valued at approximately $282,000. Franklin Resources Inc. raised its position in Cooper Companies by 194.0% in the third quarter. Franklin Resources Inc. now owns 48,892 shares of the medical device company’s stock valued at $5,265,000 after purchasing an additional 32,260 shares during the period. Finally, Principal Financial Group Inc. lifted its stake in Cooper Companies by 6.6% during the third quarter. Principal Financial Group Inc. now owns 238,305 shares of the medical device company’s stock worth $26,295,000 after purchasing an additional 14,687 shares in the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

Wall Street Analysts Forecast Growth

COO has been the topic of several research analyst reports. Robert W. Baird cut their price objective on Cooper Companies from $117.00 to $107.00 and set an “outperform” rating on the stock in a report on Friday, March 7th. BNP Paribas upgraded shares of Cooper Companies to a “hold” rating in a research note on Thursday, March 13th. Needham & Company LLC reissued a “hold” rating on shares of Cooper Companies in a research note on Friday, March 7th. Citigroup dropped their price objective on shares of Cooper Companies from $115.00 to $110.00 and set a “buy” rating for the company in a report on Friday, March 7th. Finally, Piper Sandler reiterated an “overweight” rating and set a $115.00 target price (down from $120.00) on shares of Cooper Companies in a report on Friday, March 7th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Cooper Companies presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.25.

Cooper Companies Trading Down 3.2 %

COO opened at $75.37 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91. The Cooper Companies, Inc. has a one year low of $69.81 and a one year high of $112.38. The company has a market cap of $15.07 billion, a P/E ratio of 38.65, a PEG ratio of 2.25 and a beta of 1.01. The business’s 50-day simple moving average is $84.99 and its 200-day simple moving average is $94.84.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.92. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The company had revenue of $964.70 million for the quarter, compared to analysts’ expectations of $981.25 million. As a group, equities research analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.